SCHEMBL71407

SCHEMBL71407

C=C(C)C(=O)OCCC[Si](OC(C)OCCCC)(OC(C)OCCCC)OC(C)OCCCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.53
THRB P10828 1/20 0.40
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39
HTT P42858 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HPGD P15428 2/20 0.34
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.31
LMNA P02545 2/20 0.31
CYP1A2 P05177 2/20 0.31
CYP2C19 P33261 2/20 0.31
ESR1 P03372 1/20 0.31
CYP2D6 P10635 1/20 0.31
MAPK1 P28482 1/20 0.31
NR1H2 P55055 1/20 0.31
RNASEL Q05823 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93435 0.89 TSHR (0.47) TSHRTHRBPOLBAPEX1HTT
SCHEMBL73424 0.83 TSHR (0.46) TSHRTHRBPOLBAPEX1HTT
SCHEMBL9305952 0.81 TSHR (0.59) TSHRTHRBPOLBAPEX1HTT
SCHEMBL133182 0.81 TSHR (0.50) TSHRTHRBPOLBAPEX1HTT
Alcohol SCHEMBL29001782 0.80 TSHR (0.50) TSHRTHRBPOLBAPEX1HTT
SCHEMBL1227557 0.80 TSHR (0.50) TSHRTHRBPOLBAPEX1HTT
SCHEMBL28617940 0.80 TSHR (0.49) TSHRTHRBPOLBAPEX1HTT
SCHEMBL72364 0.80 TSHR (0.62) TSHRTHRBPOLBAPEX1HTT
SCHEMBL6151602 0.79 TSHR (0.49) TSHRTHRBPOLBAPEX1HTT
SCHEMBL4019138 0.79 TSHR (0.81) TSHRTHRBPOLBAPEX1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3049483-B1 METAL EFFECT PIGMENTS MODIFIED WITH A SILANE LAYER CONTAINING AT LEAST TWO DIFFERENT BIFUNCTIONAL SILANES SCHLENK METALLIC PIGMENTS GMBH (DE) 2019-06-12 EP claimed
US-20100190637-A1 Curing Catalyst MERCK PATENT GESELLSCHAFT (DE) 2010-07-29 US claimed
EP-2160239-A1 CURING CATALYST Merck Patent GmbH (DE) 2010-03-10 EP claimed
WO-2009015713-A1 CURING ACCELERATOR MERCK PATENT GMBH (DE) 2009-02-05 WO claimed
WO-2009000378-A1 CURING CATALYST MERCK PATENT GMBH (DE) 2008-12-31 WO claimed
EP-3999019-B1 METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A COATED EFFECT PIGMENT AND A FILM-FORMING POLYMER II HENKEL AG & CO KGAA (DE) 2026-05-06 EP disclosed
US-20260007589-A1 METHOD FOR DYEING KERATINOUS MATERIAL COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, AN EFFECT PIGMENT, AND A FILM-FORMING POLYMER III HENKEL AG & CO. KGAA (DE) 2026-01-08 US disclosed
EP-3999021-B1 PROCESS FOR COLOURING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, AN EFFECT PIGMENT AND A FILM-FORMING POLYMER IV HENKEL AG & CO KGAA (DE) 2026-01-07 EP disclosed
EP-4031097-B1 PROCESS FOR COLOURING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, AN EFFECT PIGMENT AND A FILM-FORMING POLYMER IV HENKEL AG & CO KGAA (DE) 2026-01-07 EP disclosed
US-12485077-B2 Method for dyeing keratinous material, comprising the use of an organosilicon compound, an effect pigment and a post-treatment agent HENKEL AG & CO. KGAA (DE) 2025-12-02 US disclosed
EP-4007562-B1 METHOD FOR DYEING KERATIN MATERIAL, COMPRISING THE USE OF AN ORGANIC C1-C6-ALKOXY-SILANE AND AN ALKALISING AGENT HENKEL AG & CO KGAA (DE) 2025-10-22 EP disclosed
EP-4007641-B1 METHOD FOR TREATING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANIC C1-C6 ALKOXY SILANE AND AN AMINO ACID AND/OR AN AMINO ACID DERIVATIVE HENKEL AG & CO KGAA (DE) 2025-08-06 EP disclosed
WO-2007059842-A1 SILANES MERCK PATENT GMBH (DE) 2007-05-31 WO disclosed
WO-2007059841-A1 ZINC OXIDE NANOPARTICLES MERCK PATENT GMBH (DE) 2007-05-31 WO disclosed
WO-2007017195-A2 METAL EFFECT PIGMENTS COMPRISING A MIXED INORGANIC/ORGANIC LAYER, METHOD FOR THE PRODUCTION OF SUCH METAL EFFECT PIGMENTS, AND USE THEREOF ECKART GMBH (DE) 2007-02-15 WO disclosed
US-7172812-B2 surface treatment of flake metal pigment Eckart-Werke Standard Bronzepūlver-Werke Carl-Eckart GmbH & Co. (DE) 2007-02-06 US disclosed
US-20040226480-A1 surface treatment of flake metal pigment ECKART-WERKE STANDARD BRONZEPULVER-WERKE CARL-ECKART GMBH & CO. 2004-11-18 US disclosed
US-6761762-B1 AGITATING AND HEATING INITIAL PIGMENT IN ORGANIC SOLVENT, MIXING PIGMENT WITH SOLUTION OF BASE IN WATER OR ANOTHER SOLVENT, ADDING ORGANIC SOLVENT BASED SURFACE-MODIFYING AGENT TO MIXTURE, COOLING, REMOVING LIQUID TO FORM FILTER CAKE ECKART-WERKE STANDARD BRONZEPULVER-WERKER CARL-ECKART GMBH & CO. (DE) 2004-07-13 US disclosed
EP-1084198-B1 EFFECT PIGMENTS COATED WITH REACTIVE ORIENTATION AUXILIARY AGENTS ECKART STANDARD BRONZEPULVER (DE) 2002-07-24 EP disclosed
EP-0524417-A1 Coating composition and method for preparation of UV, UV/IR or IR/UV curable coatings FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 1993-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12485077-B2 Method for dyeing keratinous material, comprising the use of an organosilicon compound, an effect pigment and a post-treatment agent KRT18, KIT, MSH6 TSHR 4759/4885THRB 4345/4885POLB 439/4885
US-20260007589-A1 METHOD FOR DYEING KERATINOUS MATERIAL COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, AN EFFECT PIGMENT, AND A FILM-FORMING POLYMER III KRT18, GP6, F12 TSHR 3868/4885THRB 3766/4885POLB 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.